

Canadian Bacterial Diseases Network

[View the current Canadian Bacterial Diseases Network Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/2368-Canadian+Bacterial+Diseases+Network.html)

(<http://www.bioportfolio.com/biocorporate/2368-Canadian+Bacterial+Diseases+Network.html>)

Contact Details:

282-Heritage Medical Research Building

Calgary

Alberta

T2N 4N1

Canada

Tel: 780 220 2562

Fax: 780 283 5241

Email:

Recent Publications by Canadian Bacterial Diseases Network:



- [Biosynthesis of 2-acetamido-2,6-dideoxy-L-hexoses in bacteria follows a pattern distinct from those of the pathways of 6-deoxy-L-hexoses.](#)
*6-Deoxy-L-hexoses have been shown to be synthesized from dTDP-D-glucose or...*29th May, 2003
Canadian Bacterial Diseases Network, University of Guelph, Department of- Biochem J. 2003 May 1;371(Pt 3):989-95. ([DOI Direct Link](#))
- [Case 1: assessment. Burkholderia cepacia.](#)
*Previous studies have shown that gentamicin-induced membrane vesicles...*21st February, 2003
Division of Infectious and Immunological Diseases, Department of- Paediatr Respir Rev. 2002 Sep;3(3):273-4.
- [Advances in Burkholderia cepacia complex.](#)
*Burkholderia cepacia is an important opportunistic pathogen in certain...*21st February, 2003
Division of Infectious and Immunological Diseases, Department of- Paediatr Respir Rev. 2002 Sep;3(3):230-5.
- [Bactericidal effect of gentamicin-induced membrane vesicles derived from Pseudomonas aeruginosa PAO1 on gram-positive bacteria.](#)
*Previous studies have shown that gentamicin-induced membrane vesicles...*25th January, 2003
Canadian Bacterial Diseases Network, National Centre of Excellence and- Can J Microbiol. 2002 Sep;48(9):810-20.
- [Nonradiolabeling assay for WaaP, an essential sugar kinase involved in biosynthesis of core lipopolysaccharide of Pseudomonas aeruginosa.](#)
*waaP is present in the lipopolysaccharide (LPS) core gene clusters of a...*31st October, 2002

Canadian Bacterial Diseases Network, Department of Microbiology,- Antimicrob Agents Chemother. 2002 Jun;46(6):2035-7.

- [Bovine immunoglobulin A \(IgA\)-binding activities of the surface-expressed Mig protein of Streptococcus dysgalactiae.](#)
The Mig protein of Streptococcus dysgalactiae is a type III immunoglobulin... 22nd October, 2002
 Veterinary Infectious Disease Organization (VIDO), Saskatoon,- Microbiology. 2002 Jul;148(Pt 7):2055-64.
- [Crystal structure of Pseudomonas aeruginosa PAK pilin suggests a main-chain-dominated mode of receptor binding.](#)
Fibers of pilin monomers (pili) form the dominant adhesin of Pseudomonas... 15th July, 2000
 Department of Medical Microbiology and Immunology, Canadian Bacterial- J Mol Biol. 2000 Jun 16;299(4):1005-17. ([DOI Direct Link](#))

Press Releases on Canadian Bacterial Diseases Network:

h1n1 Pandemic Preparedness: Strengthening International Collaboration	6th November, 2009	Meridian International Center	WASHINGTON, Nov. 6 /PRNewswire-USNewswire/ -- Meridian International Center will convene government leaders, diplomats, policymakers, scientists, and public health officials in two roundtable
U.S. and European Experts Applaud Creation of New Transatlantic Task Force on Global Antibiotic Resistance Threat	6th November, 2009	Pew Health Group	WASHINGTON, Nov. 6 /PRNewswire-USNewswire/ -- Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU)
CEL-SCI to Conduct First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns Hopkins University School of Medicine	6th November, 2009	CEL-SCI Corporation	VIENNA, Va., Nov. 6 /PRNewswire/ -- CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage oncology
NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses	6th November, 2009	NexBio, Inc.	SAN DIEGO, Nov. 6 /PRNewswire/ -- NexBio Inc., in collaboration with scientists at the Centers for Disease Control and Prevention (CDC), St. Louis University, and the University of Hong Kong,

[GeoVax Labs, Inc.](#)
[Provides Third Quarter
2009 Financial Results
and Operational Update](#)

6th November, 2009 GeoVax Labs, Inc.

-- In August 2009, GeoVax received the award notice for the third year of the Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant initially awarded to the

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

